RESEARCHER PROFILE

Toby M. Maher

← Back to Imperial College London

T

Imperial College London

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) ResearchPulmonary Hypertension Research and TreatmentsSystemic Sclerosis and Related DiseasesOccupational and environmental lung diseases

Toby M. Maher works in Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Pulmonary Hypertension Research and Treatments, Systemic Sclerosis and Related Diseases, Occupational and environmental lung diseases. Recorded institutional associations include University of Southern California, University of California, Los Angeles, Royal Brompton Hospital.

965Publications
35,634Citations
97H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

    2022 · 2,827 citations
  2. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

    2019 · 1,642 citations
  3. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

    2016 · 1,437 citations
  4. Interstitial Lung Disease in Systemic Sclerosis

    2008 · 1,230 citations
  5. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis

    2013 · 805 citations
  6. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development

    2020 · 636 citations
  7. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

    2019 · 628 citations
  8. Global incidence and prevalence of idiopathic pulmonary fibrosis

    2021 · 612 citations
  9. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

    2020 · 569 citations
  10. The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis

    2014 · 566 citations
  11. Interstitial lung diseases

    2022 · 539 citations
  12. Pulmonary fibrosis secondary to COVID-19: a call to arms?

    2020 · 481 citations
  13. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes

    2012 · 392 citations
  14. Interstitial Lung Disease

    2024 · 388 citations
  15. PD-1 up-regulation on CD4 + T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production

    2018 · 363 citations
  16. Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

    2017 · 354 citations
  17. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

    2007 · 341 citations
  18. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis

    2019 · 327 citations
  19. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury

    2009 · 319 citations
  20. Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?

    2016 · 315 citations
  21. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study

    2015 · 312 citations
  22. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis

    2019 · 310 citations
  23. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

    2020 · 310 citations
  24. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study

    2017 · 296 citations
  25. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

    2019 · 296 citations

← Return to the university profile